Werewolf Therapeutics Inc (NASDAQ:HOWL) — Market Cap & Net Worth
Market Cap & Net Worth: Werewolf Therapeutics Inc (HOWL)
Werewolf Therapeutics Inc (NASDAQ:HOWL) has a market capitalization of $34.84 Million ($34.84 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23197 globally and #4827 in its home market, demonstrating a -15.94% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Werewolf Therapeutics Inc's stock price $0.72 by its total outstanding shares 48540200 (48.54 Million). Analyse Werewolf Therapeutics Inc (HOWL) cash flow conversion to see how efficiently the company converts income to cash.
Werewolf Therapeutics Inc Market Cap History: 2021 to 2026
Werewolf Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $578.11 Million to $35.09 Million (-46.20% CAGR).
Index Memberships
Werewolf Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #664 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2220 of 3165 |
Weight: Werewolf Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Werewolf Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Werewolf Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
38.11x
Werewolf Therapeutics Inc's market cap is 38.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $578.11 Million | $4.15 Million | -$49.77 Million | 139.37x | N/A |
| 2022 | $99.51 Million | $16.40 Million | -$51.56 Million | 6.07x | N/A |
| 2023 | $187.37 Million | $19.94 Million | -$37.37 Million | 9.40x | N/A |
| 2024 | $71.84 Million | $1.89 Million | -$70.52 Million | 38.11x | N/A |
Competitor Companies of HOWL by Market Capitalization
Companies near Werewolf Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Werewolf Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Werewolf Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Werewolf Therapeutics Inc's market cap moved from $578.11 Million to $ 35.09 Million, with a yearly change of -46.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $35.09 Million | +14.13% |
| 2025 | $30.75 Million | -57.20% |
| 2024 | $71.84 Million | -61.66% |
| 2023 | $187.37 Million | +88.29% |
| 2022 | $99.51 Million | -82.79% |
| 2021 | $578.11 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Werewolf Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $34.84 Million USD |
| MoneyControl | $34.84 Million USD |
| MarketWatch | $34.84 Million USD |
| marketcap.company | $34.84 Million USD |
| Reuters | $34.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies throu… Read more